These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11713942)

  • 1. High-Dose interferon-alpha2b plus ribavirin for retreatment of interferon-nonresponsive patients infected with genotype 1 hepatitis C virus.
    Buti M; Morral S; Sanchez F; Martell M; Stalgis C; Esteban R
    Dig Dis Sci; 2001 Nov; 46(11):2396-400. PubMed ID: 11713942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).
    Poynard T; Marcellin P; Lee SS; Niederau C; Minuk GS; Ideo G; Bain V; Heathcote J; Zeuzem S; Trepo C; Albrecht J
    Lancet; 1998 Oct; 352(9138):1426-32. PubMed ID: 9807989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.
    Buti M; Olive G; Stalgis C; Esteban R; Guardi J
    Dig Dis Sci; 2000 Apr; 45(4):685-9. PubMed ID: 10759235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study.
    Portal I; Bourlière M; Halfon P; De Lédinghen V; Couzigou P; Bernard PH; Blanc F; Caroli-Bosc F; Arpurt JP; Vetter D; Mathieu-Chandelier C; Chazouillères O; Thiefin G; Pol S; Sogni P; Abergel A; Bailly F; Picon M; Debonne JM; Zamora C; Alleman I; Moreau X; Doll F; Eugène C; Ducloux S; Larrey D; Ouzan D; Grimaud JC; Gouvernet J; Botti G; Gérolami V; Khiri H; Gérolami A; Gauthier AP; Botta-Fridlund D
    J Viral Hepat; 2003 May; 10(3):215-23. PubMed ID: 12753341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.
    Di Marco V; Almasio P; Vaccaro A; Ferraro D; Parisi P; Cataldo MG; Di Stefano R; Craxì A
    J Hepatol; 2000 Sep; 33(3):456-62. PubMed ID: 11020002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
    Poynard T; Marcellin P; Bissery A; Myers RP; Moussalli J; Degos F; Dhumeaux D; Riachi G; Bronowicki JP; Brissot P; Buffet C; Serfaty L; Naveau S; Sogni P; Beaugrand M; Gayno S; Larrey D; Samuel D; Eugene C; Pol S; Bedossa P; Daurat V; Chaumet-Riffaud P;
    J Viral Hepat; 2003 May; 10(3):197-204. PubMed ID: 12753338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.
    Enríquez J; Gallego A; Torras X; Pérez-Olmeda T; Diago M; Soriano V; Luján MS; García-Samaniego J
    J Viral Hepat; 2000 Nov; 7(6):403-8. PubMed ID: 11115050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.
    Sjogren MH; Sjogren R; Holtzmuller K; Winston B; Butterfield B; Drake S; Watts A; Howard R; Smith M
    Dig Dis Sci; 2005 Apr; 50(4):727-32. PubMed ID: 15844709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.
    Jessner W; Gschwantler M; Formann E; Gurguta C; Watkins-Riedel T; Wrba F; Ferenci P
    Antivir Ther; 2008; 13(4):581-9. PubMed ID: 18672537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
    Steindl-Munda P; Ferenci P; Brunner H; Nachbaur K; Datz C; Gschwantler M; Hofer H; Stauber R; Hackl F; Jessner W; Rosenbeiger M; Gangl A; Vogel W;
    Liver Int; 2003 Aug; 23(4):269-75. PubMed ID: 12895267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
    Jensen DM; Marcellin P; Freilich B; Andreone P; Di Bisceglie A; Brandão-Mello CE; Reddy KR; Craxi A; Martin AO; Teuber G; Messinger D; Thommes JA; Tietz A
    Ann Intern Med; 2009 Apr; 150(8):528-40. PubMed ID: 19380853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C.
    Cheng PN; Chow NH; Hu SC; Young KC; Chen CY; Jen CM; Chang TT
    Dig Liver Dis; 2002 Dec; 34(12):851-6. PubMed ID: 12643293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone.
    Fattovich G; Zagni I; Ribero ML; Castagnetti E; Minola E; Lomonaco L; Scattolini C; Fabris P; Boccia S; Giusti M; Abbati G; Felder M; Rovere P; Redaelli A; Tonon A; Tomba A; Montanari R; Paternoster C; Distasi M; Fornaciari G; Tositti G; Rizzo C; Suppressa S; Pantalena M; Noventa F; Tagger A
    J Viral Hepat; 2004 Nov; 11(6):543-51. PubMed ID: 15500555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
    Taliani G; Gemignani G; Ferrari C; Aceti A; Bartolozzi D; Blanc PL; Capanni M; Esperti F; Forte P; Guadagnino V; Mari T; Marino N; Milani S; Pasquazzi C; Rosina F; Tacconi D; Toti M; Zignego AL; Messerini L; Stroffolini T;
    Gastroenterology; 2006 Apr; 130(4):1098-106. PubMed ID: 16618404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
    Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
    J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection.
    Wiśniewska-Ligier M; Pawłowska M; Pilarczyk M; Halota W; Woźniakowska-Gęsicka T
    J Pediatr Gastroenterol Nutr; 2013 Dec; 57(6):694-9. PubMed ID: 23942001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy.
    Hass HG; Kreysel C; Fischinger J; Menzel J; Kaiser S
    World J Gastroenterol; 2005 Sep; 11(34):5342-6. PubMed ID: 16149143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.